<?xml version="1.0" encoding="UTF-8"?>
<p>Molecular MRD response rates were then analyzed separately in the peripheral blood 
 <italic>versus</italic> bone marrow at the mid-term follow-up time-point (after 4 treatment cycles) and at the end of treatment (after 6 cycles). Blood samples were molecular MRD-negative from 88% (50/57) of patients after four cycles and 87% (47/54 patients) after six cycles (
 <xref ref-type="fig" rid="f2-1040138">Figure 2C</xref>, left panel). The corresponding percentages for bone marrow samples were 77% (37/48 patients) after four cycles of treatment and 76% (35/46 patients) at the end of treatment (after 6 cycles) (
 <italic>Online Supplementary Figure S3</italic>).
</p>
